Europe meeting, experts discussed the challenges and strategies of small and mid-sized biopharma companies surrounding ...

AstraZeneca plans to submit the positive data Breztri Aerosphere in asthma for to regulatory authorities for review.

Pliant Therapeutics will cut 45% of its workforce in a sweeping restructuring effort aimed at extending its cash runway, the ...

Tempus AI has announced that it is using the TIME Network for Phase I trials to expedite site activation and enrolment.

Amylyx has dosed the first subject in the Phase III LUCIDITY trial of avexitide for treating post-bariatric hypoglycaemia ...

Data from the NERO study investigating Zejula in mesothelioma was presented at the American Association of Cancer Research ...

Among those consuming UPFs in high-income countries, intake varies significantly across age and socioeconomic status.

Immunic’s drug is currently being investigated in two Phase III trials in patients with relapsing multiple sclerosis.

Neurocrine has commenced a Phase III registrational programme to assess NBI-1117568 as a treatment for schizophrenia in adult ...

The FDA approved AstraZeneca's Truqap in November 2023 for the treatment of advanced HR-positive breast cancer.

The London Cancer Hub has been identified as a key district for ‘frontier innovation’ by London Mayor Sadiq Khan.

Biopharmaceutical company Cullinan Therapeutics is due to begin a trial of its drug candidate CLN-978 for treating Sjögren’s ...